Novel potent opioids require higher naloxone dosing than fentanyl, tied to high cardiac arrest rates
Synthetic opioids, particularly the potent fentanyl analogues and the relatively lesser-known nitazene drug class, are rapidly emerging as a concerning trend in the landscape of illicit drug overdose cases. These potent opioids have been causing havoc, leading to a surge in emergency department (ED) admissions. A recent cohort study, conducted from 2020 to 2022, sought to shed light on the clinical outcomes and naloxone administration in patients presenting with nitazene overdose compared to fentanyl overdose.
The study, part of the ongoing nationwide ToxIC Fentalog cohort study, focused on adults admitted to EDs who tested positive for novel potent opioids (NPOs). These NPOs included brorphine, isotonitazene, metonitazene, and N-piperidinyl etonitazene. In total, 717 patients met the inclusion criteria, with 11 (2.0%) testing positive for fentanyl only and 9 (1.7%) for NPOs.
The results revealed significant disparities in naloxone administration between the two groups. Patients in the NPO group received a substantially higher mean number of naloxone boluses during their hospital stay (1.33) compared to the fentanyl group (0.36). This marked contrast corresponded to a moderately large effect size, suggesting that NPO overdoses required more intensive intervention.
Moreover, within the NPO group, metonitazene overdoses stood out as particularly concerning. Patients overdosing on metonitazene experienced cardiac arrest, necessitating even more naloxone doses. On average, these cases required three naloxone doses, highlighting the severe nature of metonitazene overdoses. Alarmingly, all patients with metonitazene overdoses required cardiopulmonary resuscitation, underlining the life-threatening potential of this synthetic opioid.
These findings underscore the urgent need for further research and awareness regarding the management of synthetic opioid overdoses, especially nitazenes like metonitazene. The study's results suggest that these newer, potent opioids may pose a unique challenge to healthcare providers and require more aggressive naloxone intervention compared to traditional opioids like fentanyl. The battle against the opioid crisis continues, with the emergence of synthetic opioids emphasizing the need for flexibility and innovation in healthcare responses.
Source:
Amaducci, A., Aldy, K., Campleman, S. L., Li, S., Meyn, A., Abston, S., Culbreth, R. E., Krotulski, A., Logan, B., Wax, P., Brent, J., Buchanan, J., Calello, D., Judge, B., … Levine, M. (2023). Naloxone Use in Novel Potent Opioid and Fentanyl Overdoses in Emergency Department Patients. In JAMA Network Open (Vol. 6, Issue 8, p. e2331264). American Medical Association (AMA). https://doi.org/10.1001/jamanetworkopen.2023.31264
